1. Miconazole-like Scaffold is a Promising Lead for Naegleria fowleri-Specific CYP51 Inhibitors
- Author
-
Sharma, Vandna, Madia, Valentina Noemi, Tudino, Valeria, Nguyen, Jennifer V., Debnath, Anjan, Messore, Antonella, Ialongo, Davide, Patacchini, Elisa, Palenca, Irene, Basili Franzin, Silvia, Seguella, Luisa, Esposito, Giuseppe, Petrucci, Rita, Di Matteo, Paola, Bortolami, Martina, Saccoliti, Francesco, Di Santo, Roberto, Scipione, Luigi, Costi, Roberta, and Podust, Larissa M.
- Abstract
Developing drugs for brain infection by Naegleria fowleriis an unmet medical need. We used a combination of cheminformatics, target-, and phenotypic-based drug discovery methods to identify inhibitors that target an essential N. fowlerienzyme, sterol 14-demethylase (NfCYP51). A total of 124 compounds preselected in silicowere tested against N. fowleri. Nine primary hits with EC50≤ 10 μM were phenotypically identified. Cocrystallization with NfCYP51 focused attention on one primary hit, miconazole-like compound 2a. The S-enantiomer of 2aproduced a 1.74 Å cocrystal structure. A set of analogues was then synthesized and evaluated to confirm the superiority of the S-configuration over the R-configuration and the advantage of an ether linkage over an ester linkage. The two compounds, S-8band S-9b, had an improved EC50and KDcompared to 2a. Importantly, both were readily taken up into the brain. The brain-to-plasma distribution coefficient of S-9bwas 1.02 ± 0.12, suggesting further evaluation as a lead for primary amoebic meningoencephalitis.
- Published
- 2023
- Full Text
- View/download PDF